It was shown that HSP90 suppression by ganetespib impaired EGF- and HGF-induced signaling in human cancer cells, since the EGFR and c-mesenchymal–epithelial transition (c-Met) receptor (receptor to hepatocyte growth factor, HGF) systems both represent significant mediators of cancer development and metastasis. The gene discussed is EGF; the disease is cancer.